IP Library › Granted Patent US 12,195,807
Granted Patent B2
US 12,195,807 · App. 17/831,345 · Granted Jan 14, 2025

Method of treating a cancer patient without the need for a tissue biopsy

Inventors: Clive Morris (Cambridge, GB); Vincent Plagnol (Cambridge, GB); Tim Forshew (Stevenage, GB)
Assignee: INIVATA LTD.
C12Q1/6886C12Q1/6827C12Q2600/156C12Q2600/172
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,195,807
App. No.
17/831,345
Granted
Jan 14, 2025
Kind
B2
Abstract

Provided herein, among other things, is a method of treating a cancer patient without the need for a tissue biopsy. In some embodiments, the method may comprise (a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) from a sample of blood from the patient to determine if the cell-free DNA comprises actionable and/or non-actionable sequence variations in one or more target genes, and (b) treating the patient using the following method: i. administering a therapy that is targeted to an actionable sequence variation if the patient is identified as having the actionable sequence variation, and ii. administering a non-targeted therapy in the absence of any follow-up genetic testing on DNA extracted from a tissue biopsy if one or more non-actionable sequence variations and no actionable sequence variations are identified.

Claims (27)

1. A method of treatment, comprising:

(a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) isolated from the blood of a patient that has colorectal cancer, wherein the sequencing assay targets one or more mutations in KRAS and one or more actionable and non-actionable sequence variations in one or more target genes, wherein:

(i) an actionable sequence variation is a sequence variation for which there is a therapy that targets the protein encoded by the gene having the sequence variation; and

(ii) a non-actionable sequence variation is a sequence variation for which there is no therapy that targets the protein having the sequence variation;

(b) determining that the cfDNA has no mutations in KRAS and one or more non-actionable sequence variations by analyzing the results of step (a); and

(c) administering an epidermal growth factor (EGFR) inhibitor to the patient based on the determination of step (b),

wherein the decision to administer the EGFR inhibitor is made without considering data obtained from a tumor biopsy.

2. The method of claim 1 , wherein the one or more mutations in KRAS comprise mutations selected from the group consisting of the G12A, G12C, G12D, G12F, G12I, G12R, G12S, G12V, G13C, G13D, G13R, GQ60-61GK, Q61H, Q61L and Q61R mutations in the KRAS gene.

3. The method of claim 1 , wherein the method comprises:

calculating the allele frequencies of the one or more non-actionable sequence variations identified in step (b); and

calculating the probability that there are mutations in KRAS based on the allele frequencies of the one or more non-actionable sequence variations.

4. The method of claim 1 , wherein the one or more non-actionable sequence variations identified in (b) are in the APC and TP53 genes.

5. The method of claim 1 , wherein the EGFR inhibitor comprises cetuximab or panitumumab.

6. The method of claim 1 , wherein the one or more actionable sequence variations are activating mutations in the EGFR gene.

7. The method of claim 1 , further comprising:

analyzing white blood cell DNA from the patient;

determining whether any of the KRAS mutations or non-actionable sequence variations are due to hematopoiesis of indeterminate potential or a germ-line variation; and

eliminating sequence variations that are due to hematopoiesis of indeterminate potential or a germ-line variation from the analysis of step (b).

8. A method of treatment comprising:

(a) performing or having performed a sequencing assay on cell-free DNA (cfDNA) isolated from the blood of a patient that has colorectal cancer, wherein the sequencing assay targets one or more mutations in KRAS and one or more actionable and non-actionable sequence variations in one or more target genes, wherein:

(b) determining whether the cfDNA comprises one or more mutations in KRAS, and one or more actionable and non-actionable sequence variations in one or more target genes by analyzing the results of step (a), wherein:

(i) an actionable sequence variation is a sequence variation for which there is a therapy that targets the protein encoded by the gene having the sequence variation; and

(ii) a non-actionable sequence variation is a sequence variation for which there is no therapy that targets the protein having the sequence variation; and

(c) treating the patient by:

i. identifying one or more mutations in KRAS in the cfDNA and administering FOLFIRI, FOLFOX or CAPEOX+/−bevacizumab to the patient, or

ii. identifying no mutations in KRAS and one or more non-actionable sequence variations in the cfDNA and administering an epidermal growth factor (EGFR) inhibitor to the patient;

wherein the decision to administer the therapy is made without considering data from a tumor biopsy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2022
From: MORRIS, CLIVE; PLAGNOL, VINCENT; FORSHEW, TIM
To: INIVATA LTD.
Reel/Frame 060098/0456 →
Continuity (3)
Continuation 16560504 · Sep 4, 2019
Provisional Application 62727462 · Sep 5, 2018
Related Publication 20220364186A1 · Nov 17, 2022
References Cited (33)
US 10329627B1 · Beeler et al. · 2019 [cited by applicant]
US 11186878B2 · Beeler et al. · 2021 [cited by applicant]
US 20050272083A1 · Seshagiri · 2005 [cited by examiner]
US 20140288116A1 · Bandla et al. · 2014 [cited by applicant]
US 20140296081A1 · Diehn et al. · 2014 [cited by applicant]
US 20150368725A1 · Ho · 2015 [cited by examiner]
US 20210040564A1 · Beeler et al. · 2021 [cited by applicant]
Oden-Gangloff et al .British Journal of Cancer. 100: 1330-1335 (Year: 2009). [cited by examiner]
Cisowski et al., “What makes oncogenes mutually exclusive?”, Small Gtpases, 2016, 8(3): 187-192. [cited by applicant]
Ding et al., “Somatic mutations affect key pathways in lung adenocarcinoma”, Nature, 2008, 455(7216): 1069-1075. [cited by applicant]
Koivunen et al., “Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but hot Asian lung cancer patients”, British Journal of Cancer, 2008, 99: 245-252. [cited by applicant]
Leiserson et al., “A weighted exact test for mutually exclusive mutations in cancer”, Bioinformatics, 2016, 32: i736-i745. [cited by applicant]
Sparks et al., “Mutational Analysis of the APC/β-Catenin/Tcf Pathway in Colorectal Cancer”, Cancer Research, 1998, 58: 1130-1134. [cited by applicant]
Tam et al., “Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non [cited by applicant]
Bardelli et al., “Liquid Biopsies, What We Do Not Know (Yet)”, Cancer Cell, 2017, 31:172-179. [cited by applicant]
Crowley et al., “Liquid biopsy: monitoring cancer-genetics in the blood”, Nature Reviews Clinical Oncology, 2013, 10:472-484. [cited by applicant]
Durendez-Saez et al., “New insights in non-small-cell lung cancer: circulating tumor cells and cell-free DNA”, Journal of Thoracic Disease, 2017, 13:S1332-S1345. [cited by applicant]
Ettinger et al., “Non-Small Cell Lung Cancer, Version 5.2017”, Journal of the National Comprehensive Cancer Network, 2017, 15(4):504-535. [cited by applicant]
Frenel et al., “Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response to Molecularly Targeted Drug Administration”, Clinical Cancer Research, 2015, 21(20):4586-4596. [cited by applicant]
Paweletz et al., “Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients”, 2015, Clinical Cancer Research, 22 (4… [cited by applicant]
Plagnol et al., “Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling” PLoS ONE, 2018, 13(3):e0193802. [cited by applicant]
Strickler et al., “Genomic landscape of cell-free DNA in Patients with colorectal cancer” American Association for Cancer Research, 2018, 8(2):1-24. [cited by applicant]
Wills et al., “Role of liquid biopsies in colorectal cancer” Current Problems in Cancer, 2018, 42(6):593-600. [cited by applicant]
Yoneda et al., “A liquid biopsy in primary lung cancer” Surgery Today, 2019, 49:1-14. [cited by applicant]
Bernabe et al., “What do we need to make circulating tumour DNA (ctDNA) a routine diagnostic test in lung cancer?”, European Journal of Cancer, 2017, 81: 66-73. [cited by applicant]
Jenkins et al., “Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer”, Journal of Thoracic Oncology, 2017, 12(7): 1061-1070. [cited by applicant]
US Food and Drug Administration (FDA), “cobas EGFR Mutation Test v2”, Jun. 1, 2016, downloaded from the FDA's website on Oct. 17, 2021. [cited by applicant]
Thierry et al., “Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment”, Annals of Oncology, 2017, 28: 2149-2159 and Su… [cited by applicant]
Dienstmann et al., “Standardized decision support in next generation sequencing reports of somatic cancer variants”, Molecular Oncology, 2014, 8: 859-873. [cited by applicant]
Chen et al., “Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing”, 2016, 6: 31985, p. 1-8. [cited by applicant]
Arcila, “Molecular Testing of Solid Tumors”, 2012, Memorial Sloan Kettering Cancer Center, New York, NY, 2012. [cited by applicant]
Diaz et al., “Insights into therapeutic resistance from whole-genome analyses of circulating tumor DNA”, Oncotarget, 2013, 4(10): 1856-1857. [cited by applicant]
Xia et al., “Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals”, Scientific Reports, 2017, 7: 7526, p. 1-7. [cited by applicant]